

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the specification:

Listing of Claims

1. (original) A combination comprising a DPP IV inhibitor or a pharmaceutically acceptable salt thereof, and at least one therapeutic agent selected from the group consisting of
 - i) an antiobesity agent or a pharmaceutically acceptable salt thereof,
 - ii) an appetite regulating agent or a pharmaceutically acceptable salt thereof.
2. (currently amended) A pharmaceutical composition comprising the combination of claim 1 and a pharmaceutically acceptable carrier.
3. (currently amended) The combination according to claim 1 ~~or 2~~, in the form of a combined preparation or a fixed combination.
4. (currently amended) The combination according to ~~any one of the claims 1 to 3~~ claim 1, wherein the DPP-IV inhibitor is selected from 1-{2-[(5-cyanopyridin-2-yl) amino] ethylamino} acetyl-2 (S)- cyano-pyrrolidine dihydrochloride, and (S)-1-[(3-hydroxy-1-adamantyl)amino]acetyl-2-cyano-pyrrolidine, L-threo-isoleucyl thiazolidine, MK-0431, GSK23A, BMS-477118, 3-(aminomethyl)-2-isobutyl-1-oxo-4-phenyl-1,2-dihydro-6-isoquinolinecarboxamide and 2-[[3-(aminomethyl)-2-isobutyl-4-phenyl-1-oxo-1,2-dihydro-6-isoquinolyl]oxy]acetamide, and optionally in any case, a pharmaceutical salts thereof.
5. (currently amended) The combination according to ~~any one of the claims 1 to 3~~ claim 1, wherein the DPP-IV inhibitor is (S)-1 -{2-[5-cyanopyridin-2yl)amino]ethyl-aminoacetyl)-2-cyano-pyrrolidine or (S)-1 -[(3-hydroxy-1-adamantyl)amino]acetyl-2- cyano-pyrrolidine.
6. (currently amended) The combination according to ~~any one of the claims 1 to 5~~ claim 1, wherein the anti-obesity agent or appetite regulating agent is selected from the group consisting of phentermine, leptin, bromocriptine, dexamphetamine, amphetamine, fenfluramine, dexfenfluramine, sibutramine, orlistat, dexfenfluramine, mazindol, phentermine, phendimetrazine, diethylpropion, fluoxetine, bupropion, topiramate, diethylpropion, benzphetamine, phenylpropanolamine or ecopipam, ephedrine or pseudoephedrine; or, in each case, a pharmaceutically acceptable salt thereof.

7. (original) A method for the prevention of, delay of progression of, treatment of a disease or condition selected from the group consisting of
- (a) type 2 diabetes mellitus and related diseases, disorders or conditions;
 - (b) insulin resistance and syndrome X, obesity and related diseases, disorders or conditions;
 - (c) hypertension including hypertension in the elderly, familial dyslipidemic hypertension, and isolated systolic hypertension (ISH); increased collagen formation, fibrosis, and remodeling following hypertension; erectile dysfunction, impaired vascular compliance, stroke; all these diseases or conditions associated with or without hypertension;
 - (d) congestive heart failure, left ventricular hypertrophy, survival post myocardial infarction (MI), coronary artery diseases, atherosclerosis, angina pectoris, thrombosis;
 - (e) renal failure, especially chronic renal failure, glomerulosclerosis, nephropathy;
 - (f) hypothyroidism;
 - (g) endothelial dysfunction with or without hypertension;
 - (h) hyperlipidemia, hyperlipoproteinemia, hypertryglyceridemia, and hypercholesterolemia;
 - (i) macular degeneration, cataract, glaucoma;
 - (j) skin and connective tissue disorders, and
 - (k) restenosis after percutaneous transluminal angioplasty, and restenosis after coronary artery bypass surgery; peripheral vascular disease;
- comprising administering to a warm-blooded animal, including man, in need thereof a jointly effective amount of a combination of a DPP IV inhibitor or a pharmaceutically acceptable salt thereof with at least one therapeutic agent selected from the group consisting of
- (i) an antiobesity agent or a pharmaceutically acceptable salt thereof,
 - (ii) an appetite regulating agent or a pharmaceutically acceptable salt thereof;
 - (iii) a renin inhibitor or a pharmaceutically acceptable salt thereof.
8. (canceled) Use of a DPP IV inhibitor or a pharmaceutically acceptable salt thereof in combination with at least one therapeutic agent selected from the group consisting of
- i) an antiobesity agent or a pharmaceutically acceptable salt thereof,
 - ii) an appetite regulating agent or a pharmaceutically acceptable salt thereof,
- for the manufacture of a medicament for the prevention of, delay of progression of, or treatment of a disease or condition selected from the group consisting of
- (a) type 2 diabetes mellitus and related diseases, disorders or conditions (including but not limited to diabetic nephropathy, diabetic retinopathy and diabetic neuropathy);
 - (b) insulin resistance and syndrome X, obesity and related diseases, disorders or conditions (including but not limited to not limited to Insulin Resistance, Type 2 Diabetes Mellitus, Reproductive Disorders, Cardiovascular Disease, Pulmonary Disease, Gallstones and Fasting-induced cholecystitis, Cancers and Cutaneous Disease, Cushing's Syndrome, Hypothyroidism, Insulinoma, Craniopharyngioma and Other Disorders Involving the Hypothalamus);

- (c) hypertension including hypertension in the elderly, familial dyslipidemic hypertension, and isolated systolic hypertension (ISH); increased collagen formation, fibrosis, and remodeling following hypertension (antiproliferative effect of the combination); erectile dysfunction, impaired vascular compliance, stroke; all these diseases or conditions associated with or without hypertension,
- (d) congestive heart failure, left ventricular hypertrophy, survival post myocardial infarction (MI), coronary artery diseases, atherosclerosis, angina pectoris, thrombosis,
- (e) renal failure, especially chronic renal failure, glomerulosclerosis, nephropathy;
- (f) hypothyroidism;
- (g) endothelial dysfunction with or without hypertension,
- (h) hyperlipidemia, hyperlipoproteinemia, hypertriglyceridemia, and hypercholesterolemia,
- (i) macular degeneration, cataract, glaucoma,
- (j) skin and connective tissue disorders, and
- (k) restenosis after percutaneous transluminal angioplasty, and restenosis after coronary artery bypass surgery; peripheral vascular disease.

9. (canceled) A kit of parts comprising

- (a) an amount of a DPP IV inhibitor or a pharmaceutically acceptable salt thereof in a first unit dosage form;
- (b) an amount of at least one therapeutic agent selected from the group consisting of
 - (i) an antiobesity agent or a pharmaceutically acceptable salt thereof,
 - (ii) an appetite regulating agent or a pharmaceutically acceptable salt thereof, or,
 in each case, where appropriate, a pharmaceutically acceptable salt thereof, in the form of two or three or more separate units of the components (a) or (b).

10. (currently amended) The method according to claim 7, ~~use according to claim 8, kit of parts according to claim 9,~~ wherein the DPP-IV inhibitor is selected from 1-{2-[(5-cyanopyridin-2-yl) amino] ethylamino} acetyl-2 (S)- cyano-pyrrolidine dihydrochloride, and (S)-1-[(3-hydroxy-1-adamantyl)amino]acetyl-2-cyano-pyrrolidine, L-threo-isoleucyl thiazolidine, MK-0431, GSK23A, BMS-477118, 3-(aminomethyl)-2-isobutyl-1-oxo-4-phenyl-1,2-dihydro-6-isoquinolinecarboxamide and 2-[[3-(aminomethyl)-2-isobutyl-4-phenyl-1-oxo-1,2-dihydro-6-isoquinolyl]oxy]acetamide, and optionally in any case, a pharmaceutical salts thereof.

11. (currently amended) The method according to claim 7, ~~use according to claim 8, kit of parts according to claim 9,~~ wherein the anti-obesity agent or appetite regulating agent is selected from the group consisting of phentermine, leptin, bromocriptine, dexamphetamine, amphetamine, fenfluramine, dexfenfluramine, sibutramine, orlistat, dexfenfluramine, mazindol,

phentermine, phendimetrazine, diethylpropion, fluoxetine, bupropion, topiramate, diethylpropion, benzphetamine, phenylpropanolamine or ecopipam, ephedrine or pseudoephedrine;
or, in any case, a pharmaceutically acceptable salt thereof.

12. (currently amended) The method according to claim 7, ~~use according to claim 8, kit of parts according to claim 9,~~ wherein the DPP-IV inhibitor is selected from 1-{2-[(5-cyanopyridin-2-yl) amino] ethylamino} acetyl-2 (S)- cyano-pyrrolidine dihydrochloride, and (S)-1-[(3-hydroxy-1-adamantyl)amino]acetyl-2-cyano-pyrrolidine, L-threo-isoleucyl thiazolidine, MK-0431, GSK23A, BMS-477118, 3-(aminomethyl)-2-isobutyl-1-oxo-4-phenyl-1,2-dihydro-6-isoquinolinecarboxamide and 2-[[3-(aminomethyl)-2-isobutyl-4-phenyl-1-oxo-1,2-dihydro-6-isoquinolyl]oxy]acetamide, and wherein the anti-obesity agent or appetite regulating agent is selected from the group consisting of phentermine, leptin, bromocriptine, dexamphetamine, amphetamine, fenfluramine, dexfenfluramine, sibutramine, orlistat, dexfenfluramine, mazindol, phentermine, phendimetrazine, diethylpropion, fluoxetine, bupropion, topiramate, diethylpropion, benzphetamine, phenylpropanolamine or ecopipam, ephedrine or pseudoephedrine;
or, in any case, a pharmaceutically acceptable salt thereof.

13. (currently amended) The combination according to claim 2, ~~method according to claim 7, use according to claim 8, kit of parts according to claim 9,~~ wherein the DPP-IV inhibitor is (S)-1 - {2-[5-cyanopyridin-2yl)amino]ethyl-aminoacetyl)-2-cyano- pyrrolidine or (S)-1 -[(3-hydroxy-1-adamantyl)amino]acetyl-2- cyano-pyrrolidine, and wherein the anti-obesity agent or appetite regulating agent is selected from the group consisting of phentermine, leptin, bromocriptine, dexamphetamine, amphetamine, fenfluramine, dexfenfluramine, sibutramine, orlistat, dexfenfluramine, mazindol, phentermine, phendimetrazine, diethylpropion, fluoxetine, bupropion, topiramate, diethylpropion, benzphetamine, phenylpropanolamine or ecopipam, ephedrine or pseudoephedrine;
or, in any case, a pharmaceutically acceptable salt thereof.

14. (canceled) Combination according to claims 2, or 3, method according to claim 7, use according to claim 8, kit of parts according to claim 9, wherein the DPP-IV inhibitor is (S)-1 -[(3-hydroxy-1-adamantyl)amino]acetyl-2-cyano-pyrrolidine, and wherein the anti-obesity agent or appetite regulating agent is selected from the group consisting of phentermine, leptin, bromocriptine, dexamphetamine, amphetamine, fenfluramine, dexfenfluramine, sibutramine, orlistat, dexfenfluramine, mazindol, phentermine, phendimetrazine, diethylpropion, fluoxetine, bupropion, topiramate, diethylpropion, benzphetamine, phenylpropanolamine or ecopipam, ephedrine or pseudoephedrine;
or, in any case, a pharmaceutically acceptable salt thereof.

15. (currently amended) The combination according to ~~claim 2 or 3~~ claim 1, ~~method according to claim 7, use according to claim 8, kit of parts according to claim 9~~, wherein the DPP-IV inhibitor is (S)-1 -{2-[5-cyanopyridin-2yl)amino]ethyl-aminoacetyl)-2-cyano- pyrrolidine or (S)-1 -[(3-hydroxy-1-adamantyl)amino]acetyl-2-cyano-pyrrolidine, and wherein the anti-obesity agent or appetite regulating agent is selected from the group consisting of orlistat, sibutramine, diethylpropion, phen-fen and phentermine, or a pharmaceutically acceptable salt thereof.

16. (currently amended) The method according to ~~any one of claims 7, 10 to 15~~ claim 7, ~~use according to any one of claims 8, 10 to 14~~, wherein the disease or condition is selected from diabetes preferably type 2 diabetes, IGT or obesity and diseases or conditions associated with diabetes or obesity.